Terazosin
Product Images NDC 53002-1250

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 53002-1250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021250)

Packaging label for Terazosin 1 mg capsules by RPK Pharmaceuticals, Inc. The label indicates a 100-capsule bottle with directions to take one capsule daily or as directed. It includes warnings about dizziness, hypotension risk, and standard medication information, as well as placeholders for patient name and clinic information.*

FDA Label Image

Label Image (Lbl530021726)

Terazosin 2mg capsules packaging label showing 30 capsules per container. The label includes directions to take 1 capsule daily or as directed, mentions the labeler as RPK Pharmaceuticals, Inc., and displays lot number, expiration date, and billing NDC information. Placeholder text indicates areas for patient name, clinic name, and prescribing information.*

FDA Label Image

Label Image (Lbl530021727)

Terazosin 5 mg capsules packaging label from RPK Pharmaceuticals, Inc. The label indicates a bottle containing 30 capsules with directions to take one capsule daily or as directed. The label includes fields for patient name, prescription details, lot number, and doctor information, with cautionary statements and storage instructions.*

FDA Label Image

Label Image (Lbl530021728)

Terazosin 10 mg capsules packaging label from RPK Pharmaceuticals, Inc. The label indicates a bottle containing 30 capsules. It includes dosage instructions to take 1 capsule daily or as directed, a barcode, a lot number, expiration date, and placeholder text for patient and clinic names.*

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure diagram of Terazosin hydrochloride, illustrating the molecular arrangement and bonding of the active ingredient Terazosin with the hydrochloride component.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This figure presents two line graphs illustrating the mean change over three months for 'Total Symptom Score from Baseline' and 'Peak Flow Rate (mL/sec) from Baseline' comparing Terazosin and placebo treatments. The graphs show data points, error bars, and sample sizes (N) for each group across the time course.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph showing mean change from baseline over a 30-month period, with the x-axis labeled in months and the y-axis representing the mean change value. Data points are marked at various time intervals with some points indicated by asterisks, suggesting statistically significant changes.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph illustrating the mean change from baseline in an unspecified measure over a 30-month period for Terazosin. The x-axis represents months (0 to 30), and the y-axis shows the mean change values. Data points indicate an increasing trend with error bars and statistical significance marked by asterisks at multiple time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.